REGN

Regeneron Pharmaceuticals
D

REGN

606.12
USD
15.98
(2.71%)
مغلق
حجم التداول
54,752
الربح لكل سهم
35
العائد الربحي
0.15
P/E
15
حجم السوق
65,440,047,042
أصول ذات صلة
AMGN
AMGN
-2.15
(-0.76%)
281.20 USD
BIIB
BIIB
2.500
(2.07%)
123.460 USD
BMY
BMY
1.000
(2.02%)
50.560 USD
GILD
GILD
0.420
(0.41%)
103.660 USD
INCY
INCY
0.500
(0.81%)
62.500 USD
MRK
MRK
-0.090
(-0.11%)
83.160 USD
PFE
PFE
0.065
(0.27%)
24.185 USD
VRTX
VRTX
2.22
(0.45%)
500.92 USD
المزيد
الأخبار المقالات

العنوان: Regeneron Pharmaceuticals

القطاع: Healthcare
الصناعة: Biotechnology
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approvedfor wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).